Clinical trial
A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening…
NCT00001038 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00001038 |
|---|---|
| Title | A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients |
| Official title | A Randomized, Double-Blind Trial of Valacyclovir Hydrochloride (BW 256U87) Prophylaxis for Opportunistic Cytomegalovirus End-Organ Disease in Patients With Advanced HIV Infection (< 100 CD4+ Lymphocytes) |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Glaxo Wellcome Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cytomegalovirus Infections, HIV Infections |
| Intervention type | Drug |
| Interventions | Valacyclovir hydrochloride, Acyclovir |
| Enrollment | 1,200 |
| Primary completion | May 1, 1996 |
| First posted | Aug 31, 2001 |
| Last update posted | Mar 1, 2011 |
| Countries | Australia, Canada, Denmark, France, Germany, Italy, Sweden, Switzerland, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: